Have you or your loved ones been diagnosed with locally advanced or metastatic solid tumors?

You may be eligible to participate in a locally advanced or metastatic solid tumors clinical trial.

Have you or your loved ones been diagnosed with locally advanced or metastatic solid tumors? You may be eligible to participate in a locally advanced or metastatic solid tumors clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Locally Advanced or Metastatic Solid Tumors Clinical Trial
NCT03150810 | Phase 1 phase 2 | Interventional
BeiGene
Sponsored by
BeiGene

Have you or your loved ones been diagnosed with locally advanced or metastatic solid tumors?

You may be eligible to participate in a locally advanced or metastatic solid tumors clinical trial.

Have you or your loved ones been diagnosed with locally advanced or metastatic solid tumors? You may be eligible to participate in a locally advanced or metastatic solid tumors clinical trial.

Completed

Male & Female

18 - 99

Years old

This study has recruited 139 Participants

The primary objective of this study is to determine the safety and tolerability of pamiparib, the maximum tolerated dose (MTD) or maximum administered dose (MAD) for pamiparib combined with TMZ, to select the recommended Phase 2 dose (RP2D) and schedule of pamiparib in combination with TMZ, and to determine the antitumor activity of pamiparib in combination with TMZ.